Analyst consensus rating
Palvella Therapeutics Analyst Rating: Strong Buy
Direct answer
Palvella Therapeutics's consensus rating is Strong Buy.
15 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $228.40.
Forecast evidence checked November 3, 2026.
Get free Palvella Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $146.33
- Average price target
- $228.40
- High price target
- $267.00
- Low price target
- $205.00
- Low target gap
- +40.1%
- Target upside
- +56.1%
- High target gap
- +82.5%
- Target range width
- 42.4%
- Consensus rating
- Strong Buy
- Analysts
- 15
- Evidence date
- November 3, 2026
- Valid through
- November 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Palvella Therapeutics?
Palvella Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $228.40.
How far are Palvella Therapeutics's low and high targets from the recorded price?
The low target implies +40.1%, while the high target implies +82.5%.
How many analysts are included in Palvella Therapeutics's consensus?
The verified consensus includes 15 analysts.
How is Palvella Therapeutics's target upside or downside calculated?
The average target of $228.40 is divided by the recorded price of $146.33, then one is subtracted to produce +56.1%. This does not guarantee a future return.
When was Palvella Therapeutics's analyst forecast verified?
The data was verified on 2026-11-03. The dataset is valid through 2026-11-10.